AbbVie - 11 Year Stock Price History | ABBV

Historical daily share price chart and data for AbbVie since 2013 adjusted for splits and dividends. The latest closing stock price for AbbVie as of May 17, 2024 is 166.42.
  • The all-time high AbbVie stock closing price was 180.38 on March 28, 2024.
  • The AbbVie 52-week high stock price is 182.89, which is 9.9% above the current share price.
  • The AbbVie 52-week low stock price is 130.96, which is 21.3% below the current share price.
  • The average AbbVie stock price for the last 52 weeks is 154.38.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
AbbVie Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2024 168.6304 156.8113 180.3771 156.8113 166.4200 9.45%
2023 142.8642 153.1250 158.4416 127.3202 152.0526 -0.23%
2022 138.1115 122.8806 160.4359 121.0239 152.3988 24.04%
2021 100.7502 91.2889 123.3434 89.6272 122.8625 32.40%
2020 77.1339 73.5476 94.1121 53.6827 92.7958 27.61%
2019 62.5512 69.3462 74.1225 50.9847 72.7180 1.50%
2018 74.4464 73.6277 92.8417 60.5021 71.6466 -0.98%
2017 55.5943 45.0345 73.4781 43.7486 72.3558 60.13%
2016 43.1556 39.9923 48.1793 35.9244 45.1860 9.88%
2015 42.5256 44.2670 48.9829 33.5086 41.1238 -6.46%
2014 36.8251 33.8146 46.8334 30.7089 43.9647 27.97%
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $293.876B $54.318B
AbbVie has become one of the top-most pharma companies after it acquired Allergan. The deal has transformed AbbVie's portfolio by lowering its dependence on Humira, its flagship product. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest immunology drugs Skyrizi and Rinvoq position it well for long-term growth. AbbVie came into existence after Abbott Laboratories divested its pharmaceutical division. AbbVie enjoys leadership positions in key therapeutic areas including immunology, hematologic oncology, neuroscience, aesthetics, eye care and womens' health. Humira is approved for several autoimmune diseases like rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis, Crohn's disease and others. Imbruvica became part of the company's portfolio following the Pharmacyclics acquisition. Other key drugs include Venclexta, Botox Cosmetic, Botox Therapeutics, Vraylar, Skyrizi and Rinvoq.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $731.812B 105.77
Novo Nordisk (NVO) Denmark $591.861B 45.48
Johnson & Johnson (JNJ) United States $372.169B 14.78
Merck (MRK) United States $332.279B 60.46
AstraZeneca (AZN) United Kingdom $238.424B 20.73
Novartis AG (NVS) Switzerland $209.653B 14.86
Pfizer (PFE) United States $162.291B 20.17
Sanofi (SNY) $123.116B 11.62
Innoviva (INVA) United States $0.998B 7.01